Mauhin, Wladimir
Guffon, Nathalie
Vanier, Marie T.
Froissart, Roseline
Cano, Aline
Douillard, Claire
Lavigne, Christian
Héron, Bénédicte
Belmatoug, Nadia
Uzunhan, Yurdagül
Lacombe, Didier
Levade, Thierry
Duvivier, Aymeric
Pulikottil-Jacob, Ruth
Laredo, Fernando
Pichard, Samia
Lidove, Olivier http://orcid.org/0000-0003-4847-7839
,
Abi-Wardé, Marie-Thérèse
Berger, Marc
Berthoux, Emilie
Cabannes-Hamy, Aurélie
Camou, Fabrice
Cathebras, Pascal
Grobost, Vincent
Keraen, Jérémy
Kuster, Alice
Lioger, Bertrand
Mehdaoui, Anas
Merlot, Claire
Michaud, Martin
Reynaud-Gaubert, Martine-Louise
Schlemmer, Fréderic
Servettaz, Amélie
Stavris, Chloé
Trouillier, Sébastien
Funding for this research was provided by:
Sanofi
Article History
Received: 6 February 2024
Accepted: 27 May 2024
First Online: 5 August 2024
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and all subsequent amendments, the guidelines for Good Epidemiology Practice, Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology, all national laws and regulations of France (where the study was performed), and any applicable guidelines. The necessary regulatory submission (ethics committee) was performed in accordance with local regulations, including local data protection regulations. A written and signed informed consent was obtained from alive participants or their legal representatives. The study was approved by Health Data Hub on 9th March, 2021.
: Not applicable.
: WM has received honoraria from Amicus, Sanofi, Chiesi and Takeda; consultation fees from Chiesi and Sanofi. NG has received honoraria or consultation fees from Sanofi, Ultragenyx, and Chiesi; PI in ASCEND-PED, a Sanofi-sponsored trial. MTV has received honoraria from Orphazyme, Orchard Therapeutics, and Sanofi. RF has received honoraria from Sanofi, Takeda, and Chiesi; travel fees and accommodation from Amicus. AC has received honoraria from Sanofi. CD has received honoraria from Ultragenyx and Sanofi. CL has received honoraria or consultation fees from Sanofi and Boehringer Ingelheim. BH has received honoraria from Takeda and Orchard; travel fees and accommodation from Chiesi, PTC Therapeutics; PI in trials sponsored by JR Pharmaceuticals, Chiesi, Orphazyme, Lysogene and Mallincrodt. NB has received consultation fees for speaking, education, clinical trials and research from Sanofi and Takeda. YU has received consulting fees and honoraria for speaking, or educational events from Boehringer-Ingelheim, Sanofi, GSK, Pfizer, and Oxyvie. DL has participated in a Board with Sanofi. TL has received consulting fees from Sanofi and Chiesi. AD and RP-J are employees and may hold stocks and/or stock options in Sanofi. FL was an employee of Sanofi at the time of study conduct. SP has received honoraria from Sanofi and Biomarin; travel fees and accommodation from Sanofi, Biomarin and Takeda. OL has received honoraria from Amicus, Sanofi, and Chiesi; PI in ASCEND, a Sanofi-sponsored trial; consultation fees from Amicus and Sanofi.